LifeScience
eXmoor Pharma, the integrated cell and gene therapy CDMO with embedded consultancy expertise, and Siam Bioscience, a leading biopharmaceutical company in A...
September 24, 2025 | News
Akeso Inc. has announced that the first patient has been dosed in its registrational Phase II study (AK130-202), evaluating AK130, a fully independent...
September 23, 2025 | News
SOPHiA GENETICS an AI technology company transforming precision medicine announced an expansion of its collaboration with AstraZeneca (LSE/STO/Nasdaq:...
September 23, 2025 | News
Study confirms the novelty and atomic-level precision of de novo antibody design, including cryo-EM validation on a designed anti-PD-L1 antibody Finding...
September 23, 2025 | News
Thermo Fisher Scientific, the world leader in serving science, has introduced the Thermo Scientific™ Hypulse™ Surface Analysis System. This inn...
September 23, 2025 | News
CorestemChemon Inc. announced that it has presented key findings from the Phase 3 ALSummit trial of Neuronata-R® (lenzumestrocel) an autolo...
September 22, 2025 | News
Breakthrough high-performance computing solution delivers 3x higher throughput, cost efficiency, and faster life-saving discoveries Lenovo shared updates ...
September 22, 2025 | News
EYLUXVI® is the second biosimilar approved for Alteogen following the launch of the Herceptin® biosimilar in China through it...
September 18, 2025 | News
Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SH) and Aditum Bio announced the launch of Kalexo Bio, a new company formed in conjunction with an exc...
September 18, 2025 | News
Phrontline Biopharma, a clinical-stage biotechnology company advancing a new generation of Antibody-Drug Conjugates (ADCs), today announced that the first ...
September 16, 2025 | News
BGE-102, an orally available, brain-penetrant NLRP3 inhibitor, was developed from a hit compound identified using HitGen's industry-leading DEL technolog...
September 16, 2025 | News
Alphamab Oncology announced that the New Drug Application (NDA) for anbenitamab injection (KN026), independently developed by the Company and co-developed ...
September 15, 2025 | News
Nanjing Leads Biolabs Co., announced the first patient has been successfully dosed in a Phase 1b/II clinical trial (NCT07099430) evaluating Opamt...
September 15, 2025 | News
YolTech Therapeutics, a clinical-stage biotech company pioneering in vivo genome editing therapies, today announced the closing of its approximately $...
September 12, 2025 | News
Most Read
Bio Jobs
News
Editor Picks